Immunogenicity and safety of heterologous versus homologous prime-boost schedules with inactivated and adenoviral vectored SARS-CoV-2 vaccines – A prospective multi-center study

Background: During the peak of Coronavirus disease (COVID-19) pandemic in Thailand when the emergence of delta variant reduced the efficacy of inactivated vaccine, Thailand had abundance of inactivated vaccine but mRNA vaccine was not available and the supply of adenoviral-vectored vaccine was limit...

Popoln opis

Bibliografske podrobnosti

Principais autores:	Pawat Phuensan, Jarongkorn Sirimongkolkasem, Terapong Tantawichien, Jeerath Phannajit, Stephen J. Kerr, Pokrath Hansasuta, Prawat Chantharit, Adisorn Wongsa, Pusit Fuengfoo, Anutra Chittinandana, Kriengsak Vareesangthip, Methee Chayakulkeeree, Sureeporn Jangsirikul, Araya Schmidt, Kanyika Wanvimonsuk, Poramed Winichakoon, Rattagan Kajeekul, Wichai Prayoonwiwat, Rungsun Rerknimitr
Format:	Artigo
Jezik:	Inglês
Izdano:	Elsevier 2024-01-01
Serija:	Heliyon
Online dostop:	http://www.sciencedirect.com/science/article/pii/S2405844023104543
Oznake:	Označite Brez oznak, prvi označite!